Clinical Trial Update: Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab in combination with dabrafenib and trametinib before surgery for BRAF-mutated anaplastic thyroid carcinoma; the study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Thyroid Carcinoma
• Thyroid Squamous Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• MEKINIST (trametinib)
• TAFINLAR (DABRAFENIB)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING